// App-Quantinova.ai

: A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Researchers

Presenter

  • Brian J Ball

Principal Investigators

  • Eytan Stein

  • Marjorie Robbins

  • Jianying Zhang

  • Ross L. Levine

  • Timothy Synold

  • Anthony S. Stein

  • Guido Marcucci

  • Yilun Liu

  • Alexey V Danilov

Medical Centers

  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

  • Department of Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, CA

  • Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Computational and Quantitative Medicine-BRI, City of Hope National Medical Center, Duarte, CA

  • Department of Cancer Genetics and Epigenetics, City of Hope National Medical Center, Duarte, CA

  • Department of Cancer Biology, City of Hope, Duarte, CA

  • Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

  • Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Patched 1

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • E3 ubiquitin-protein ligase CBL

  • KRAS proto-oncogene, GTPase

  • GTPase Nras

  • Tet methylcytosine dioxygenase 2

  • Isocitrate dehydrogenase 2

  • Neurofibromatosis type 1

Drug/Treatment

  • Cobimetinib

  • Enasidenib

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

  • KRAS

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved